Association of sirolimus with pericardial effusion in renal transplant patient and discussion of potential mechanism

Meng, Lingbin; Deng, Bo; Liu, Baoqiong; Gordon, Dwayne

doi:10.1136/bcr-2019-230269

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Common side effects include diarrhea, nausea, constipation, skin rash, and headache. Rare but life-threatening side effects include lymphoma and other malignancy, interstitial pneumonia, lymphocytic meningitis, and pericardial effusion [3].…”

Section: Discussionmentioning

confidence: 99%

Hemopericardium in a Sirolimus-Treated Renal Transplant Patient

Groudan

Sawalha

Bhat

et al. 2020

Cureus

View full text Add to dashboard Cite

Sirolimus is an immunosuppressant frequently prescribed to prevent graft-vs-host disease in renal transplant patients. Pericardial effusion is recognized as a rare and potentially lethal side effect of this medication. Hemopericardium, specifically, is an even rarer complication that has yet to be reported in the literature. We report the first case of sirolimus-induced hemopericardium in a renal transplant patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Hemopericardium in a Sirolimus-Treated Renal Transplant Patient

Groudan

Sawalha

Bhat

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…The purpose of this study was to examine the effectiveness of β-tricalcium phosphate (TCP)/PLGA scaffolds with in situ loaded of rapamycin in lumbar fusion. As an inhibitor of m-TORC1, rapamycin has been proven to promote bone regeneration through multiple signaling pathways, but its systemic medication can cause severe side effects such as small bowel angioedema, hypertriglyceridemia, and pericardial effusion (Lai et al, 2019;Meng et al, 2019;Yang et al, 2018). Therefore, the development of a TCP/PLGA composite scaffold that can locally release rapamycin to promote spinal fusion after spinal surgery has a splendid clinical application prospect.…”

mentioning

confidence: 99%

TCP/PLGA composite scaffold loaded rapamycin in situ enhances lumbar fusion by regulating osteoblast and osteoclast activity

Hai

Zhu

Cheng

et al. 2021

J Tissue Eng Regen Med

View full text Add to dashboard Cite

The purpose of this study was to develop a novel β-tricalcium phosphate (TCP)/poly (D,L-lactic-co-glycolic acid) (PLGA) composite scaffold loaded with rapamycin that can regulate the activity of osteoblasts and osteoclasts for lumbar fusion. The TCP/ PLGA composite scaffold was fabricated by cryogenic three-dimensional printing techniques and then loaded with rapamycin in situ. The structural surface morphology of the composite scaffold was tested with scanning electron microscope. To evaluate the biocompatibility of the composite scaffold in vitro, bone marrow mesenchymal stem cells (BMSCs) were cultured on the TCP/PLGA composite scaffold slide and tested with Live/Dead Viability Kit. The effect of rapamycin on osteoclast and osteoblast was studied with staining and Western blotting. The in vitro results showed that the rapamycin-loaded TCP/PLGA composite scaffold showed good biocompatibility with BMSC and released rapamycin obviously promoted the osteoblast differentiation and mineralization. In vivo study, the TCP/ PLGA composite scaffold loaded with rapamycin were implanted in lumbar fusion model and study with micro-computed tomography scanning, hematoxylin-eosin, Masson, and immune-histological staining, to evaluate the effect of rapamycin on bone fusion. The in vivo results demonstrated that rapamycin-loaded TCP/PLGA composite scaffold could enhance bone formation by regulating osteoblast and osteoclast activity, respectively. In this study, the TCP/PLGA composite scaffold loaded with rapamycin was confirmed to provide great compatibility and improved performance in lumbar fusion by regulating osteoblastic and osteoclastic activity and would be a promising composite biomaterial for bone tissue engineering.

show abstract

Sirolimus

2019

Reactions Weekly

View full text Add to dashboard Cite

Association of sirolimus with pericardial effusion in renal transplant patient and discussion of potential mechanism

Cited by 3 publications

References 11 publications

Hemopericardium in a Sirolimus-Treated Renal Transplant Patient

Hemopericardium in a Sirolimus-Treated Renal Transplant Patient

TCP/PLGA composite scaffold loaded rapamycin in situ enhances lumbar fusion by regulating osteoblast and osteoclast activity

Sirolimus

Contact Info

Product

Resources

About